During Friday’s current trade, Shares of Apple Inc. (NASDAQ:AAPL), gained 0.08%, and is now trading at $129.78.
At CIBC’s 148th Annual General Meeting, the bank declared the launch of its new CIBC Mobile Banking app for Apple Watch. Delivering this new way to bank continues CIBC’s track record of putting banking innovations into the hands of our clients.
The new CIBC Mobile Banking Apple Watch app will allow clients to:
- Check their account balance at a Glance
- Transfer funds between accounts
- Review recent transactions
- Find their nearest CIBC branch or ATM and get directions to it on their watch
CIBC Mobile Banking is already recognized as best in class, having been recognized by Forrester Research, Inc. with the top overall ranking for mobile banking functionality in Canada among the big 5 banks evaluated in the 2014 Canadian Mobile Banking Functionality Benchmark report. Adding the CIBC Mobile Banking App for Apple Watch gives CIBC clients another option to bank when, where and how they want.
CIBC’s track record for innovation comprises being the first bank to deliver a mobile banking app in 2010 on the iPhone, delivered a first of its kind mobile payments app in 2012, and was first among the Big 5 to deliver eDeposit to clients in 2013, allowing them to deposit cheques simply by taking a picture with their mobile device.
The CIBC Mobile Banking app for Apple Watch is now accessible in the Apple Watch App Store. The CIBC Mobile Banking app for iPhone is also accessible from the App Store.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
During morning trade, Shares of Guaranty Bancorp (NASDAQ:GBNK), dropped -6.05%, and is now trading at $15.84.
Guaranty Bancorp, declared first quarter 2015 net income of $5.1 million or $0.24 per basic and diluted common share, an enhance of $1.5 million or $0.07 per basic and diluted common share as contrast to the first quarter 2014.
The Company’s net income raised $1.5 million, or 43.5% for the first quarter 2015, as contrast to the same quarter in the preceding year, due to a $2.0 million improvement in interest income; a $0.5 million decline in interest expense and a $0.5 million enhance in noninterest income. The $2.0 million enhance in interest income was driven by a $198.5 million enhance in average loans for the quarter ended March 31, 2015 combined with a $0.7 million enhance in loan fees as contrast to the first quarter of 2014. The $0.5 million decrease in interest expense during the first quarter 2015, as contrast to the same quarter in 2014, was mostly the result of the prepayment of $90.0 million of high-cost Federal Home Loan Bank (FHLB) term advances during the fourth quarter 2014. The $0.5 million enhance in noninterest income in the first quarter 2015 as contrast to the first quarter 2014 was primarily due to an enhance in investment administration and trust income. The Company’s acquisition of Cherry Hills Investment Advisors during the third quarter 2014 contributed $0.3 million in investment administration and trust income during the first quarter 2015.
Guaranty Bancorp operates as the bank holding company for Guaranty Bank and Trust Company that provides various banking products and services to consumers, and small to medium-sized businesses.
Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), during its Friday’s current trading session fell -55.80%, and is now trading at $14.58.
Aerie Pharmaceuticals, stated the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM contrast to twice-daily timolol, the most widely used comparator in registration trials for glaucoma. However, RhopressaTM demonstrated non-inferiority contrast to timolol for patients in the study with IOP below 26 millimeters of mercury (mmHg) at all nine measured time points and numerical superiority over timolol at the majority of measured time points.
Triple-Action RhopressaTM Phase 3 Highlights for Rocket 1
- RhopressaTM did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for RhopressaTM contrast to twice-daily timolol, based upon IOP measurements at the end of week 2, week 6 and day 90. The Rocket 1 study comprised of 182 patients in the RhopressaTM once-daily arm and 188 patients in the timolol twice-daily arm. The baseline IOPs tested in the study ranged from above 20 to below 27 mmHg. In addition, the results showed a slight loss of efficacy in the week 6 and day 90 measurements. Across the RhopressaTM study of 182 patients, 36 patients or about 20 percent showed signs of loss of efficacy during the study. The primary adverse event was hyperemia, which was practiced by about 35 percent of the RhopressaTM patients, of which 80 percent was stated as mild.
- Based on further analysis, RhopressaTM demonstrated non-inferiority contrast to timolol for patients in the study with IOPs below 26mmHg at all nine measured time points and numerical superiority over timolol at the majority of measured time points. The Baltimore Eye Survey points to about 80 percent of newly diagnosed glaucoma patients having IOPs of 26mmHg or less. In addition, RhopressaTM demonstrated, in a pre-specified analysis, non-inferiority to timolol and numerical superiority over timolol at all nine measured time points for patients in the study with IOPs below 24mmHg. We also noted that the number of RhopressaTM patients that practiced loss of efficacy over time was reduced to half for patients with IOPs less than 26mmHg, and the frequency of such occurrence progressively reduced for RhopressaTM patients with lower IOPs.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.
Finally, Starbucks Corporation (NASDAQ:SBUX), gained 4.45% Friday, hitting its highest level.
Starbucks Corporation, stated financial results for its 13-week fiscal second quarter and 26-week fiscal year to date ended March 29, 2015. All per-share data has been adjusted for the stock split declared on March 18, 2015 and effected on April 9, 2015. Q2 FY15 GAAP results comprise Starbucks Japan acquisition-related items; non-GAAP results exclude these items.
Q2 Fiscal 2015 Highlights:
- Global comparable store sales raised 7%, with a 3% enhance in traffic
- Americas comp sales raised 7%, with a 2% enhance in traffic
- CAP comp sales raised 12%, driven by a 10% enhance in traffic
- EMEA comp sales raised 2%, driven by a 2% enhance in traffic
- Merged net revenues raised 18% to $4.6 billion
- Channel Development revenues grew 16% to $428.0 million
- Merged operating income of $777.5 million, up 21% over Q2 of FY14
- Non-GAAP operating income of $789.4 million, up 23% over Q2 of FY14
- Merged operating margin of 17.0% raised 40 basis points over Q2 of FY14
- Non-GAAP operating margin of 17.3% raised 70 basis points over Q2 of FY14
- GAAP and non-GAAP earnings per share of $0.33, up 18% over Q2 of FY14
- The company opened 210 net new stores in Q2, counting its 5,000th store in China/Asia Pacific, bringing total stores worldwide to 22,088
- Year over year comp store transactions raised over 10 million in the U.S., over 14 million globally
- The company added a record 1.3 million new My Starbucks Rewards members in Q2 - bringing total active membership to 10.3 million - and realized a Q2 record $1.1 billion in Starbucks Card loads.
Starbucks Corporation operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates in four segments: Americas; Europe, Middle East, and Africa; China/Asia Pacific; and Channel Development.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
